Pharmacogenomics of inhaled corticosteroids and leukotriene modifiers: a systematic review

Clinical and Experimental Allergy

Volumn 47, Issue 2, 2017, Pages 271-293

  Farzan, N ^a,b   Vijverberg, S J H ^a,b   Arets, H G ^c   Raaijmakers, J A M ^a   Maitland van der Zee, A H ^a,b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

asthma; inhaled corticosteroids; leukotriene modifiers; pharmacogenetics; pharmacogenomics

Indexed keywords

ALLANTOICASE; ARACHIDONATE 5 LIPOXYGENASE; CELL NUCLEUS RECEPTOR; CORTICOSTEROID; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; IMMUNOGLOBULIN FC FRAGMENT; LEUKOTRIENE A4 HYDROLASE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; PEPTIDOLEUKOTRIENE; TRANSCRIPTION FACTOR T BET; ANTIASTHMATIC AGENT;

ASTHMA; DISEASE EXACERBATION; EMBASE; GENE EXPRESSION; GENE REPLICATION; GENETIC VARIABILITY; GENOME-WIDE ASSOCIATION STUDY; HUMAN; LUNG FUNCTION; MEDLINE; PHARMACOGENETIC TESTING; PHARMACOGENETICS; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; ALLELE; ANIMAL; GENETIC VARIATION; GENETICS; IMMUNOLOGY; META ANALYSIS; METABOLISM; PHARMACOGENETIC VARIANT; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ALLELES; ANIMALS; ANTI-ASTHMATIC AGENTS; ASTHMA; GENETIC VARIATION; HUMANS; LEUKOTRIENE ANTAGONISTS; PHARMACOGENETICS; PHARMACOGENOMIC VARIANTS; TREATMENT OUTCOME;

EID: 85006515627     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/cea.12844     Document Type: Review

References (93)

1. Global Initiative for Asthma (GINA). From the Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA), 2015. Available from: http://www.ginasthma.org/
2. Szefler SJ, Phillips BR, Martinez FD et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol 2005; 115:233–42.
3. Malmstrom K, Rodriguez-Gomez G, Guerra J et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group. Ann Intern Med 1999; 130:487–95.
4. Drazen JM, Silverman EK, Lee TH. Heterogeneity of therapeutic responses in asthma. Br Med Bull 2000; 56:1054–70.
5. Chung KF, Godard P, Adelroth E et al. Difficult/therapy-resistant asthma: the need for an integrated approach to define clinical phenotypes, evaluate risk factors, understand pathophysiology and find novel therapies. ERS Task Force on Difficult/Therapy-Resistant Asthma. European Respiratory Society. Eur Respir J 1999; 13:1198–208.
6. Sarpong E, Changes in Adult Asthma Medication Use and Expenditures, United States, 1998–1999 to 2008–2009. Statistical Brief #374. July 2012. Agency for Healthcare Research and Quality, Rockville, MD. http://www.meps.ahrq.gov/mepsweb/data_files/publicati
7. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids–new mechanisms for old drugs. N Engl J Med 2005; 353:1711–23.
8. Horvath G, Wanner A. Inhaled corticosteroids: effects on the airway vasculature in bronchial asthma. Eur Respir J 2006; 27:172–87.
9. Barnes PJ, Adcock IM. How do corticosteroids work in asthma? Ann Intern Med 2003; 139(5 Pt 1):359–70.
10. Lima JJ, Blake KV, Tantisira KG, Weiss ST. Pharmacogenetics of asthma. Curr Opin Pulm Med 2009; 15:57–62.
11. Drazen JM, Israel E, O'Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 1999; 340:197–206.
12. Israel E, Chervinsky PS, Friedman B et al. Effects of montelukast and beclomethasone on airway function and asthma control. J Allergy Clin Immunol 2002; 110:847–54.
13. Haughney J, Price D, Kaplan A et al. Achieving asthma control in practice: understanding the reasons for poor control. Respir Med 2008; 102:1681–93.
14. McGhan SL, MacDonald C, James DE et al. Factors associated with poor asthma control in children aged five to 13 years. Can Respir J 2006; 13:23–9.
15. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009; 62:1006–12.
16. Hawkins GA, Lazarus R, Smith RS et al. The glucocorticoid receptor heterocomplex gene STIP1 is associated with improved lung function in asthmatic subjects treated with inhaled corticosteroids. J Allergy Clin Immunol 2009; 123(1376–1383):e7.
17. Hosking L, Bleecker E, Ghosh S et al. GLCCI1 rs37973 does not influence treatment response to inhaled corticosteroids in white subjects with asthma. J Allergy Clin Immunol 2014; 133:587–9.
18. Perin P, Berce V, Potocnik U. CD14 gene polymorphism is not associated with asthma but rather with bronchial obstruction and hyperreactivity in Slovenian children with non-atopic asthma. Respir Med 2011; 105(Suppl):S54–9.
19. Chang HS, Heo J-S, Shin S-W et al. Association between TAAR6 polymorphisms and airway responsiveness to inhaled corticosteroids in asthmatic patients. Pharmacogenet Genomics 2015; 25:334–42.
20. Cho S-H, Park B-L, Shin SW et al. Association between WDR21A polymorphisms and airway responsiveness to inhaled corticosteroids in asthmatic patients. Pharmacogenet Genomics 2012; 22:327–35.
21. Balantic M, Rijavec M, Skerbinjek Kavalar M et al. Asthma treatment outcome in children is associated with vascular endothelial growth factor A (VEGFA) polymorphisms. Mol Diagn Ther 2012; 16:173–80.
22. Dijkstra A, Postma DS, Bruinenberg M et al. SERPINE1 -675 4G/5G polymorphism is associated with asthma severity and inhaled corticosteroid response. Eur Respir J 2011; 38:1036–43.
23. Berce V, Potocnik U. Functional polymorphism in CTLA4 gene influences the response to therapy with inhaled corticosteroids in Slovenian children with atopic asthma. Biomarkers 2010; 15:158–66.
24. Berce V, Kozmus CEP, Potočnik U. Association among ORMDL3 gene expression, 17q21 polymorphism and response to treatment with inhaled corticosteroids in children with asthma. Pharmacogenomics J 2013; 13:523–9.
25. Ym Y, Hy L, Kim S. Pharmacogenetic study of the effects of NK2R G231E G>A and TBX21 H33Q C>G polymorphisms on asthma control during inhaled corticosteroid treatment. Clin Pharmacol Ther 2009; 85:S76.
26. Lopert A, Rijavec M, Zavbi M, Korošec P, Fležar M. Asthma treatment outcome in adults is associated with rs9910408 in TBX21 gene. Sci Rep 2013; 3:2915.
27. Kim M-H, Kim S-H, Kim Y-K et al. A polymorphism in the histone deacetylase 1 gene is associated with the response to corticosteroids in asthmatics. Korean J Intern Med 2013; 28:708–14.
28. Raeiszadeh Jahromi S, Mahesh PA, Jayaraj BS, Holla AD, Vishweswaraiah S, Ramachandra NB. IL-10 and IL-17F Promoter Single Nucleotide Polymorphism and Asthma: A Case-Control Study in South India. Lung 2015; 193:739–47.
29. Leusink M, Vijverberg SJH, Koenderman L et al. Genetic variation in uncontrolled childhood asthma despite ICS treatment. Pharmacogenomics J 2015; 12:1–6.
30. Izuhara Y, Matsumoto H, Kanemitsu Y et al. GLCCI1 variant accelerates pulmonary function decline in patients with asthma receiving inhaled corticosteroids. Allergy 2014; 69:668–73.
31. Vonk JM, Postma DS, Maarsingh H, Bruinenberg M, Koppelman GH, Meurs H. Arginase 1 and arginase 2 variations associate with asthma, asthma severity and β2 agonist and steroid response. Pharmacogenet Genomics 2010; 20:179–86.
32. Ierodiakonou D, Postma DS, Koppelman GH et al. E-cadherin gene polymorphisms in asthma patients using inhaled corticosteroids. Eur Respir J 2011; 38:1044–52.
33. Tantisira KG, Hwang ES, Raby BA et al. TBX21: a functional variant predicts improvement in asthma with the use of inhaled corticosteroids. Proc Natl Acad Sci USA 2004; 101:18099–104.
34. Raby BA, Van Steen K, Lasky-Su J, Tantisira K, Kaplan F, Weiss ST. Importin-13 genetic variation is associated with improved airway responsiveness in childhood asthma. Respir Res 2009; 10:67.
35. Jin Y, Hu D, Peterson EL et al. Dual-specificity phosphatase 1 as a pharmacogenetic modifier of inhaled steroid response among asthmatic patients. J Allergy Clin Immunol 2010; 126:618–25.e1-2.
36. Stockmann C, Fassl B, Gaedigk R et al. Fluticasone propionate pharmacogenetics: CYP3A4*22 polymorphism and pediatric asthma control. J Pediatr 2013; 162:1227–7, 1227.e1-2.
37. Vijverberg SJH, Tavendale R, Leusink M et al. Pharmacogenetic analysis of GLCCI1 in three north European pediatric asthma populations with a reported use of inhaled corticosteroids. Pharmacogenomics 2014; 15:799–806.
38. Koster ES, Maitland-van der Zee A-H, Tavendale R et al. FCER2 T2206C variant associated with chronic symptoms and exacerbations in steroid-treated asthmatic children. Allergy 2011; 66:1546–52.
39. Mougey EB, Chen C, Tantisira KG et al. Pharmacogenetics of asthma controller treatment. Pharmacogenomics J 2013; 13:242–50.
40. Szczepankiewicz A, Breborowicz A, Sobkowiak P, Popiel A. No association of glucocorticoid receptor polymorphisms with asthma and response to glucocorticoids. Adv Med Sci 2008; 53:245–50.
41. Hunninghake GM, Soto-Quirós ME, Avila L et al. Polymorphisms in IL13, total IgE, eosinophilia, and asthma exacerbations in childhood. J Allergy Clin Immunol 2007; 120:84–90.
42. Rogers AJ, Tantisira K, Fuhlbrigge AL et al. Predictors of poor response during asthma therapy differ with definition of outcome. Pharmacogenomics 2009; 10:1231–42.
43. Tantisira KG, Silverman ES, Mariani TJ et al. FCER2: a pharmacogenetic basis for severe exacerbations in children with asthma. J Allergy Clin Immunol 2007; 120:1285–91.
44. Tantisira KG, Lasky-Su J, Harada M et al. Genomewide association between GLCCI1 and response to glucocorticoid therapy in asthma. N Engl J Med 2011; 365:1173–83.
45. Tantisira KG, Damask A, Szefler SJ et al. Genome-wide association identifies the T gene as a novel asthma pharmacogenetic locus. Am J Respir Crit Care Med 2012; 185:1286–91.
46. Park H-W, Dahlin A, Tse S et al. Genetic predictors associated with improvement of asthma symptoms in response to inhaled corticosteroids. J Allergy Clin Immunol 2014; 133:664–9.e5.
47. Park T-J, Park J-S, Cheong HS et al. Genome-wide association study identifies ALLC polymorphisms correlated with FEV₁ change by corticosteroid. Clin Chim Acta 2014; 436:20–6.
48. The Childhood Asthma Management Program (CAMP): design, rationale, and methods. Childhood Asthma Management Program Research Group. Control Clin Trials 1999; 20:91–120.
49. Nandi D, Tahiliani P, Kumar A, Chandu D. The ubiquitin-proteasome system. J Biosci 2006; 31:137–55.
50. Vigetti D, Monetti C, Acquati F, Taramelli R, Bernardini G. Human allantoicase gene: cDNA cloning, genomic organization and chromosome localization. Gene 2000; 256:253–60.
51. Dautzenberg FM, Hauger RL. The CRF peptide family and their receptors: yet more partners discovered. Trends Pharmacol Sci 2002; 23:71–7.
52. Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 1995; 332:1351–62.
53. Tantisira KG, Lake S, Silverman ES et al. Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. Hum Mol Genet 2004; 13:1353–9.
54. Dijkstra A, Koppelman GH, Vonk JM, Bruinenberg M, Schouten JP, Postma DS. Pharmacogenomics and outcome of asthma: no clinical application for long-term steroid effects by CRHR1 polymorphisms. J Allergy Clin Immunol 2008; 121:1510–3.
55. Acharya M, Borland G, Edkins AL et al. CD23/FcεRII: molecular multi-tasking. Clin Exp Immunol 2010; 162:12–23.
56. Lima JJ, Zhang S, Grant A et al. Influence of leukotriene pathway polymorphisms on response to montelukast in asthma. Am J Respir Crit Care Med 2006; 173:379–85.
57. Telleria JJ, Blanco-Quiros A, Varillas D et al. ALOX5 promoter genotype and response to montelukast in moderate persistent asthma. Respir Med 2008; 102:857–61.
58. Drazen JM, Yandava CN, Dubé L et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat Genet 1999; 22:168–70.
59. Tantisira KG, Lima J, Sylvia J, Klanderman B, Weiss ST. 5-Lipoxygenase pharmacogenetics in asthma: overlap with Cys-leukotriene receptor antagonist loci. Pharmacogenet Genomics 2009; 19:244–7.
60. Klotsman M, York TP, Pillai SG et al. Pharmacogenetics of the 5-lipoxygenase biosynthetic pathway and variable clinical response to montelukast. Pharmacogenet Genomics 2007; 17:189–96.
61. Asano K, Nakade S, Shiomi T et al. Impact of pharmacokinetics and pharmacogenetics on the efficacy of pranlukast in Japanese asthmatics. Respirology 2009; 14:822–7.
62. Sampson AP, Siddiqui S, Buchanan D et al. Variant LTC(4) synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast. Thorax 2000; 55(Suppl 2):S28–31.
63. Kotani H, Kishi R, Mouri A et al. Influence of leukotriene pathway polymorphisms on clinical responses to montelukast in Japanese patients with asthma. J Clin Pharm Ther 2012; 37:112–6.
64. Tcheurekdjian H, Via M, Giacomo AD et al. ALOX5AP and LTA4H polymorphisms modify augmentation of bronchodilator responsiveness by leukotriene modifiers in Latinos. J Allergy Clin Immunol 2010; 126:853–8.
65. Mastalerz L, Nizankowska E, Sanak M et al. Clinical and genetic features underlying the response of patients with bronchial asthma to treatment with a leukotriene receptor antagonist. Eur J Clin Invest 2002; 32:949–55.
66. Fowler SJ, Hall IP, Wilson AM, Wheatley AP, Lipworth BJ. 5-Lipoxygenase polymorphism and in-vivo response to leukotriene receptor antagonists. Eur J Clin Pharmacol 2002; 58:187–90.
67. Currie GP, Lima JJ, Sylvester JE, Lee DKC, Cockburn WJR, Lipworth BJ. Leukotriene C4 synthase polymorphisms and responsiveness to leukotriene antagonists in asthma. Br J Clin Pharmacol 2003; 56:422–6.
68. Pasaje CFA, Kim J-H, Park B-L et al. Association of the variants in AGT gene with modified drug response in Korean aspirin-intolerant asthma patients. Pulm Pharmacol Ther 2011; 24:595–601.
69. Kim J-H, Lee S-Y, Kim H-B et al. TBXA2R gene polymorphism and responsiveness to leukotriene receptor antagonist in children with asthma. Clin Exp Allergy 2008; 38:51–9.
70. Kang M-J, Kwon J-W, Kim B-J et al. Polymorphisms of the PTGDR and LTC4S influence responsiveness to leukotriene receptor antagonists in Korean children with asthma. J Hum Genet 2011; 56:284–9.
71. Lee S-Y, Kim H-B, Kim J-H et al. Responsiveness to montelukast is associated with bronchial hyperresponsiveness and total immunoglobulin E but not polymorphisms in the leukotriene C4 synthase and cysteinyl leukotriene receptor 1 genes in Korean children with exercise-induced asthma (EIA). Clin Exp Allergy 2007; 37:1487–93.
72. Kang M-J, Lee S-Y, Kim H-B et al. Association of IL-13 polymorphisms with leukotriene receptor antagonist drug responsiveness in Korean children with exercise-induced bronchoconstriction. Pharmacogenet Genomics 2008; 18:551–8.
73. Asano K, Shiomi T, Hasegawa N et al. Leukotriene C4 synthase gene A(-444)C polymorphism and clinical response to a CYS-LT(1) antagonist, pranlukast, in Japanese patients with moderate asthma. Pharmacogenetics 2002; 12:565–70.
74. Mougey EB, Feng H, Castro M, Irvin CG, Lima JJ. Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response. Pharmacogenet Genomics 2009; 19:129–38.
75. Kim K-A, Lee H-M, Joo H-J, Park I-B, Park J-Y. Effects of polymorphisms of the SLCO2B1 transporter gene on the pharmacokinetics of montelukast in humans. J Clin Pharmacol 2013; 53:1186–93.
76. Tapaninen T, Karonen T, Backman JT, Neuvonen PJ, Niemi M. SLCO2B1 c.935G>A single nucleotide polymorphism has no effect on the pharmacokinetics of montelukast and aliskiren. Pharmacogenet Genomics 2013; 23:19–24.
77. Dahlin A, Litonjua A, Irvin CG et al. Genome-wide association study of leukotriene modifier response in asthma. Pharmacogenomics J 2016; 16:151–7.
78. Dahlin A, Litonjua A, Lima JJ et al. Genome-Wide Association Study Identifies Novel Pharmacogenomic Loci For Therapeutic Response to Montelukast in Asthma. PLoS One 2015; 10:e0129385.
79. Holzmann J, Frank P, Löffler E, Bennett KL, Gerner C, Rossmanith W. RNase P without RNA: identification and functional reconstitution of the human mitochondrial tRNA processing enzyme. Cell 2008; 135:462–74.
80. Ellinghaus D, Ellinghaus E, Nair RP et al. Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci. Am J Hum Genet 2012; 90:636–47.
81. Mizuochi T, Matthews TJ, Kato M et al. Diversity of oligosaccharide structures on the envelope glycoprotein gp 120 of human immunodeficiency virus 1 from the lymphoblastoid cell line H9. Presence of complex-type oligosaccharides with bisecting N-acetylglucosamine residues. J Biol Chem 1990; 265:8519–24.
82. Lin C, Smith ER, Takahashi H et al. AFF4, a component of the ELL/P-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia. Mol Cell 2010; 37:429–37.
83. Peters-Golden M, Henderson WR. Leukotrienes. N Engl J Med 2007; 357:1841–54.
84. Lam BK, Owen WF, Austen KF, Soberman RJ. The identification of a distinct export step following the biosynthesis of leukotriene C4 by human eosinophils. J Biol Chem 1989; 264:12885–9.
85. In KH, Asano K, Beier D et al. Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. J Clin Invest 1997; 99:1130–7.
86. Hall IP, Blakey JD. Genetic association studies in Thorax. Thorax 2005; 60:357–9.
87. Gail MH, Pfeiffer RM, Wheeler W, Pee D. Probability of detecting disease-associated single nucleotide polymorphisms in case-control genome-wide association studies. Biostatistics 2008; 9:201–15.
88. Eberle MA, Ng PC, Kuhn K et al. Power to detect risk alleles using genome-wide tag SNP panels. PLoS Genet 2007; 3:1827–37.
89. Freedman ML, Reich D, Penney KL et al. Assessing the impact of population stratification on genetic association studies. Nat Genet 2004; 36:388–93.
90. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 2006; 38:904–9.
91. Ortega VE, Meyers DA. Pharmacogenetics: implications of race and ethnicity on defining genetic profiles for personalized medicine. J Allergy Clin Immunol 2014; 133:16–26.
92. Fleming L, Murray C, Bansal AT et al. The burden of severe asthma in childhood and adolescence: results from the paediatric U-BIOPRED cohorts. Eur Respir J 2015; 46:1322–33.
93. Lane S, Molina J, Plusa T. An international observational prospective study to determine the cost of asthma exacerbations (COAX). Respir Med 2006; 100:434–50.